{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:55:33Z","timestamp":1783461333015,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijgc.2026.104556","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:36:59Z","timestamp":1772483819000},"page":"104556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-3539","authenticated-orcid":false,"given":"Jonathan A.","family":"Ledermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Bruchim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Huzarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pilar","family":"Barretina-Ginesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pipitone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mileshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjoung-Won","family":"Park-Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-6346","authenticated-orcid":false,"given":"Ingrid","family":"Boere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mikheeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-9436","authenticated-orcid":false,"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4098-1320","authenticated-orcid":false,"given":"Gustavo","family":"Girotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-8981","authenticated-orcid":false,"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2026.104556_bib1","article-title":"Summary of product characteristics","year":"2024","journal-title":"AstraZeneca"},{"key":"10.1016\/j.ijgc.2026.104556_bib2","article-title":"Highlights of prescribing information","year":"2023","journal-title":"AstraZeneca"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104556_bib3","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104556_bib4","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104556_bib5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijgc.2026.104556_bib6","unstructured":"ICH Topic E 6 (R1) Guideline for Good Clinical Practice. European Medicines Agency. 1996. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e6-r1-guideline-good-clinical-practice_en.pdf. [Accessed 6 November 2019]."},{"issue":"2","key":"10.1016\/j.ijgc.2026.104556_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"suppl 15","key":"10.1016\/j.ijgc.2026.104556_bib8","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1200\/JCO.2017.35.15_suppl.5533","article-title":"Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)","volume":"35","author":"Gourley","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104556_bib9","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ijgc.2026.104556_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5550","article-title":"Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)","volume":"33","author":"Matulonis","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ijgc.2026.104556_bib11","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104556_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ygyno.2021.07.016","article-title":"Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial","volume":"163","author":"Colombo","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104556_bib13","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial","volume":"38","author":"Penson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104556_bib14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue--mechanisms, risk factors, and treatments","volume":"11","author":"Bower","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104556_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/2278-330X.149942","article-title":"Cancer related fatigue: a ubiquitous problem yet so under reported, under recognized and under treated","volume":"4","author":"Kapoor","year":"2015","journal-title":"S Asian J Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104556_bib16","first-page":"4","article-title":"Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition","volume":"34","author":"Vogelzang","year":"1997","journal-title":"Semin Hematol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104556_bib17","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1634\/theoncologist.2015-0268","article-title":"Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer","volume":"21","author":"Moore","year":"2016","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104556_bib18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104556_bib19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.annonc.2022.02.222","article-title":"The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2\/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer","volume":"33","author":"Francis","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104556_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.6004\/jnccn.2022.7101","article-title":"Evaluation of scores to reflect toxicity impact on quality of life of patients with platinum-resistant ovarian cancer: Aurelia substudy","volume":"21","author":"Lequesne","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijgc.2026.104556_bib21","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.2147\/CMAR.S200524","article-title":"Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer","volume":"11","author":"Jiang","year":"2019","journal-title":"Cancer Manag Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26000885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26000885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:07:57Z","timestamp":1777885677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26000885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1048891X26000885"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104556","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104556"}}